Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-ND 4.0JVS-Vascular Science

Treatment with an anti-interleukin-1β antibody does not impact aortic aneurysm progression in a rupture-prone rat model

7 affiliations
  1. 1Division of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO
  2. 2Cardiovascular Research Innovation in Surgery and Engineering Center, Department of Surgery, Washington University School of Medicine, St. Louis, MO
  3. 3Department of Radiology, Washington University School of Medicine, St. Louis, MO
  4. 4Division of Molecular Cell Biology, Washington University School of Medicine, St. Louis, MO
  5. 5Division of Surgical Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO
  6. 6Department of Biomedical Engineering, McKelvey School of Engineering, Washington University School of Medicine, St. Louis, MO
  7. 7Department of Surgery, Veterans Affairs St. Louis Health Care System, St. Louis, MO

Abstract

Abdominal aortic aneurysm (AAA) is a life-threatening inflammatory vascular disease with no effective medical therapies to mitigate its progression and rupture. Although interleukin-1 beta (IL-1β) plays a central role in AAA pathobiology, the specific impact of its inhibition on progression and rupture remains unclear. This study evaluated whether selective antibody-mediated IL-1β inhibition can reduce aneurysm progression in a rupture-prone AAA model in rats. Infrarenal AAAs were induced in male and female Sprague-Dawley rats (N = 30). The 14-day cohort included n = 5/sex/treatment group, whereas the day 6 inflammatory analyses included male rats only (n = 5/treatment group). AAAs were induced using intraluminal porcine pancreatic elastase alongside oral β-aminopropionitrile administration to promote AAA rupture. After 3 days, rats received a neutralizing anti-IL-1β antibody or a control immunoglobulin G twice weekly. Aneurysm growth, rupture incidence, and histopathology were assessed over 14 days. Results demonstrated that treatment with anti-IL-1β antibody did not significantly impact aneurysm progression, rupture rates, collagen content, or elastin degradation in either sex. Although upstream inflammatory mediators remained unchanged, in male rats assessed at day 6, treatment with the neutralizing anti-IL-1β antibody was associated with significantly reduced IL-10 and interferon-γ levels within aneurysmal tissue, alongside a trend toward reduced CD206 expression. These findings suggest that IL-1β plays a multifaceted role in maintaining counter-regulatory immune responses in established AAA, indicating that treatment with anti-IL-1β antibody did not demonstrate measurable structural benefit under the experimental conditions examined.

Clinical relevance: Abdominal aortic aneurysm (AAA) is a life-threatening condition with no effective medical treatments to prevent its progression and rupture. Interleukin-1 beta (IL-1β) is essential for AAA formation, as evidenced by the significant attenuation of aneurysm formation in IL-1β receptor knockout models. However, our study demonstrated that treatment with a neutralizing anti-IL-1β antibody did not significantly alter AAA growth or rupture rates in a rupture-prone rat model. These results indicate that anti-IL-1β antibody treatment initiated after aneurysm induction may have limited efficacy in this short-term rupture-prone model, but these findings do not exclude a potential effect of IL-1β inhibition during earlier stages of aneurysm formation. However, as pharmacodynamic target engagement was not directly quantified, incomplete IL-1β neutralization cannot be excluded.

Related

  1. A single-cell atlas of intracranial aneurysm progression identifies a dysfunctional VSMC subpopulation associated with rupture risk.
    Xiangrong Chen, Bikun Liu, Xiaofeng Zhou +6
    BMC neurosciencePeer-reviewedCC BY-NC-NDFull textNeurologyEurope PMCDOAJ
  2. Rupture of a Splenic Artery Aneurysm After Thrombolysis Mimicking a Pancreatic Cyst
    Noriyuki Kobayashi, Hideo Tokuyama, Shota Yamanaka +2
    Circulation JournalPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaJ-STAGE
  3. Evaluation of rupture risk of pediatric intracranial aneurysm using high-resolution magnetic resonance imaging techniques: a case report.
    Xin Feng, Lele Dai, Wenxin Chen +7
    BMC neurologyPeer-reviewedCC BYFull textNeurologyEurope PMCPMC
  4. Delayed Posterior Choroidal Artery Aneurysm Formation and Rupture in a Postsuperior Temporal Artery to Middle Cerebral Artery Bypass Moyamoya Disease Patient
    William Wei Hsu, Ryerson Emil Magdaleno Rosario Soliven, Yutaka Igarashi +3
    Journal of Neurological Surgery ReportsPeer-reviewedCC BYFull textNeurologyEurope PMCPMC
  5. Spontaneous rupture of an intrasplenic arterial aneurysm presenting as an acute abdomen: CT diagnosis and surgical management
    Ilyass Laaribi, MD, Safaa Kachmar, MD, Ikram Zaid, MD +2
    Radiology Case ReportsPeer-reviewedCC BYFull textGeneral medicineDOAJ
BibTeX
@article{soltan2026treatment,
  title = {{Treatment with an anti-interleukin-1β antibody does not impact aortic aneurysm progression in a rupture-prone rat model}},
  author = {Omar Soltan and Santiago Elizondo-Benedetto and Ryan Wahidi and Batool Arif and Sergio Sastriques-Dunlop and Mohamed S. Zaghloul and Mohamed A. Zayed},
  journal = {JVS-Vascular Science},
  year = {2026},
  month = oct,
  doi = {10.1016/j.jvssci.2026.100458},
  url = {https://doi.org/10.1016/j.jvssci.2026.100458},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Treatment with an anti-interleukin-1β antibody does not impact aortic aneurysm progression in a rupture-prone rat model
AU  - Omar Soltan
AU  - Santiago Elizondo-Benedetto
AU  - Ryan Wahidi
AU  - Batool Arif
AU  - Sergio Sastriques-Dunlop
AU  - Mohamed S. Zaghloul
AU  - Mohamed A. Zayed
PY  - 2026
DA  - 2026/10/07
JO  - JVS-Vascular Science
DO  - 10.1016/j.jvssci.2026.100458
UR  - https://doi.org/10.1016/j.jvssci.2026.100458
AB  - Abdominal aortic aneurysm (AAA) is a life-threatening inflammatory vascular disease with no effective medical therapies to mitigate its progression and rupture. Although interleukin-1 beta (IL-1β) plays a central role in AAA pathobiology, the specific impact of its inhibition on progression and rupture remains unclear. This study evaluated whether selective antibody-mediated IL-1β inhibition can reduce aneurysm progression in a rupture-prone AAA model in rats. Infrarenal AAAs were induced in male and female Sprague-Dawley rats (N = 30). The 14-day cohort included n = 5/sex/treatment group, whereas the day 6 inflammatory analyses included male rats only (n = 5/treatment group). AAAs were induced using intraluminal porcine pancreatic elastase alongside oral β-aminopropionitrile administration to promote AAA rupture. After 3 days, rats received a neutralizing anti-IL-1β antibody or a control immunoglobulin G twice weekly. Aneurysm growth, rupture incidence, and histopathology were assessed over 14 days. Results demonstrated that treatment with anti-IL-1β antibody did not significantly impact aneurysm progression, rupture rates, collagen content, or elastin degradation in either sex. Although upstream inflammatory mediators remained unchanged, in male rats assessed at day 6, treatment with the neutralizing anti-IL-1β antibody was associated with significantly reduced IL-10 and interferon-γ levels within aneurysmal tissue, alongside a trend toward reduced CD206 expression. These findings suggest that IL-1β plays a multifaceted role in maintaining counter-regulatory immune responses in established AAA, indicating that treatment with anti-IL-1β antibody did not demonstrate measurable structural benefit under the experimental conditions examined.  Clinical relevance: Abdominal aortic aneurysm (AAA) is a life-threatening condition with no effective medical treatments to prevent its progression and rupture. Interleukin-1 beta (IL-1β) is essential for AAA formation, as evidenced by the significant attenuation of aneurysm formation in IL-1β receptor knockout models. However, our study demonstrated that treatment with a neutralizing anti-IL-1β antibody did not significantly alter AAA growth or rupture rates in a rupture-prone rat model. These results indicate that anti-IL-1β antibody treatment initiated after aneurysm induction may have limited efficacy in this short-term rupture-prone model, but these findings do not exclude a potential effect of IL-1β inhibition during earlier stages of aneurysm formation. However, as pharmacodynamic target engagement was not directly quantified, incomplete IL-1β neutralization cannot be excluded.
SN  - 2666-3503
ER  -